Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 7/20 | 0.58 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235432 | 0.87 | TGM2 (0.61) | TGM2BTKTRPV1MAP2K7EGFR | |
| SCHEMBL30935191 | 0.87 | TGM2 (0.61) | TGM2BTKTRPV1MAP2K7EGFR | |
| SCHEMBL16193308 | 0.87 | TGM2 (0.54) | TGM2BTKTRPV1MAP2K7EGFR | |
| SCHEMBL29246639 | 0.86 | TGM2 (0.59) | TGM2BTKTRPV1MAP2K7EGFR | |
| Acrylamide SCHEMBL30480310 | 0.82 | TGM2 (0.55) | TGM2BTKTRPV1MAP2K7EGFR | |
| Acrylamide SCHEMBL22206248 | 0.82 | TGM2 (0.55) | TGM2BTKTRPV1MAP2K7EGFR | |
| SCHEMBL4103284 | 0.81 | TGM2 (0.76) | TGM2BTKMAP2K7EGFRJAK3 | |
| SCHEMBL23199033 | 0.80 | TDP1 (0.54) | TGM2BTKTRPV1MAP2K7EGFR | |
| SCHEMBL30480308 | 0.80 | TGM2 (0.50) | TGM2BTKTRPV1MAP2K7EGFR | |
| SCHEMBL9945928 | 0.80 | ALDH1A1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280827-A1 | POLYMERS, HYDROGELS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280827-A1 | POLYMERS, HYDROGELS, AND USES THEREOF | BOLA2; BOLA2B, PARG, BRAP | TGM2 2085/4885BTK 255/4885TRPV1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.